Introduction Abrogation of mitosis is an extremely competent rationale for anticancer treatment.Some natural products (NPs) work by targeting the mitotic regulatory machinery thereby restraining the efficacy of the mitotic spindle, blocking the cell division process and pushing the cells to apoptosis.Hence, NPs that hinder the advancement of mitosis are the most sought after chemotherapeutics, currently.These natural antimitotic products and their derivatives are referred to as spindle poisons/ toxins, are among the most frequently used anti-cancer drugs globally e.g.Vinca alkaloids (vincristine, vinblastine) and taxanes (e.g. paclitaxel, docetaxel).In the past, a variety of drugs that target microtubules and hampers the utility of the mitotic spindle have been used clin. for managing a wide range of human malignancies.Conversely, due to severe undesirable mechanism-based cytotoxicity in the CNS and therapeutic resistance which are repetitively seen at the time of microtubule-targeting, the use of these drugs is limited.The new generation of mitotic drugs aims for the mitotic regulatory machinery which involves the motor proteins, mitotic kinesins, or the Aurora and polo-like kinases and complexes which are expressed only at the time of cell division.Research efforts are intended towords developing superior antimitotic drugs that would not be only more specific in their action but would also lessen the burden of side effects on patients.Also, because cancer cells demonstrate vast phenotypic miscellany they are characteristically responsive to phenotypic screening which would assist in translating the mol. mechanism as a therapeutic approach in treating cancer with familiar cellular phenotypes following the theory of mechanism-informed phenotypic screening.